Cerity Partners’s Enanta Pharmaceuticals ENTA Stock Holding History

Cerity Partners’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-9,010	Closed	-$278K	–	369
2017 Q1	$278K	Buy	+9,010	New	+$281K	0.02%	355

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Cerity Partners's ENTA Position: Q2 2017 in Review

Cerity Partners sold out of Enanta Pharmaceuticals (ENTA) in Q2 2017, closing a stake of 9,010 shares — an estimated $278K sold.

Cerity Partners first reported a position in ENTA in Q1 2017 and held it in 1 quarter. The position peaked at $278K in Q1 2017. 122 funds tracked by Wall St. Rank hold ENTA as of Q2 2017.

Cerity Partners reported no remaining Enanta Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Cerity Partners sold 9,010 Enanta Pharmaceuticals shares in Q2 2017, an estimated $278K.
Cerity Partners first reported a position in Enanta Pharmaceuticals in Q1 2017 and held it in 1 quarter.
Cerity Partners's Enanta Pharmaceuticals position peaked at $278K in Q1 2017.
122 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2017.

Based on Cerity Partners's 13F filing for Q2 2017, filed 10 Aug 2017.